A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression
Phase of Trial: Phase I/II
Latest Information Update: 07 Apr 2017
At a glance
- Drugs Pacritinib (Primary) ; Sirolimus; Tacrolimus
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 30 Mar 2017 Status changed from not yet recruiting to recruiting.
- 25 Jan 2017 Planned initiation date changed from 1 Feb 2017 to 30 Apr 2017.